Course Directors

Raed A. Dweik
Raed A. Dweik, MBBS, FCCP

Associate Professor and Director
Cleveland Clinic Foundation
Cleveland, Ohio

Gustavo A. Heresi
Gustavo A. Heresi, MD

Pulmonary Vascular Program
Pulmonary, Allergy and Critical Care Medicine
Respiratory Institute
Cleveland Clinic
Cleveland, OH

Franck Rahaghi
Franck Rahaghi, MD

Chairman, Department of Pulmonary Medicine
Director, Advanced Lung Disease Program
Respiratory Center Quality Officer
Director, Pulmonary Hypertension Clinic
Respiratory Center
Cleveland Clinic Florida
Weston, FL


William R. Auger, MD

Professor of Clinical Medicine
Director, CTEPH Program
University of California, San Diego
La Jolla, CA

Charles D. Burger
Charles D. Burger, MD

Consultant, Department of Critical Care
Consultant, Division of Pulmonary Medicine
Department of Internal Medicine Mayo Clinic
Associate Professor of Medicine, College of Medicine
Mayo Clinic, Jacksonville, FL

Harrison W. Farber
Harrison W. Farber, MD

Professor of Medicine
Director, Pulmonary Hypertension Center
Boston University School of Medicine

Wassim H. Fares, MD, MSc

Assistant Professor of Medicine
Director, Pulmonary Vascular Disease Center
Pulmonary, Critical Care, and Sleep Medicine
Department of Internal Medicine
Yale School of Medicine
New Haven, CT

Anna R. Hemnes, MD

Associate Professor of Medicine
Assistant Director, Pulmonary Vascular Center
Allergy, Pulmonary, and Critical Care Medicine
Department of Medicine
Vanderbilt University Medical Center
Nashville, TN

Irene Marthe Lang, MD

Division of Cardiology
Medical University of Vienna/Allgemeines Krankenhaus
Vienna, Austria

Accredited by

Cleveland Clinic Center for Continuing Education

Course Description

Learning Objectives
1. Describe the frequency, severity, and treatment of pulmonary hypertension as a complication of chronic obstructive pulmonary disease and interstitial lung disease
2. Describe the properties of novel anticoagulants to be able to prescribe them according to specific patient characteristics
3. Detail the expected adverse events associated with pulmonary hypertension therapeutics and discuss their management
4. Discuss the pharmacoeconomics of pulmonary hypertension therapeutics and review new findings exploring cost effectiveness of care
5. Discuss the shift toward early and upfront combination therapy
6. Explain the importance of the ventilation-perfusion lung scan in the screening for chronic thromboembolic pulmonary 7. Identify the role of multidisciplinary teams in the management of acute pulmonary embolism
8. Recognize when to refer patients with suspected or known CTEPH to specialized centers for surgical evaluation
9. Summarize the evidence base supporting recent clinical developments in the pathobiology epidemiology, diagnosis, and treatment of acute and chronic pulmonary embolism

Activity Details

Credit Types:CME
Credit Amount:1.00 Credits
Release Date:2018-May-18
Expiration Date:2020-May-18
Estimated Time for Completion:1 hour
Registration Required:Yes

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.